Heterogeneous activation of protein kinase C during rat liver regeneration induced by carbon tetrachloride administration

Yutaka Sasaki, Norio Hayashi, Toshifumi Ito, Hideyuki Fusamoto, Nobuhiro Sato and Takenobu Kamada

First Department of Medicine, Osaka University Medical School, 1-1-50 Fukushima, Fukushima-ku, Osaka 553, Japan

Received 30 June 1989

During rat liver regeneration induced by carbon tetrachloride administration, the protein kinase C α subspecies was activated in a heterogeneous fashion, a higher number of hepatocytes expressing the protein kinase C α subspecies being detected in the pericentral zone than in the periportal zone. This zonal heterogeneity became maximal at 24 h after the treatment. The distribution of hepatocytes expressing the protein kinase C α subspecies was roughly coincident with that of hepatocytes exhibiting DNA synthesis. These results suggest that protein kinase C may play a crucial role in liver regeneration.

Protein kinase C; Liver regeneration; Carbon tetrachloride administration; DNA synthesis

1. INTRODUCTION

Liver regeneration provides a good model for studying cell growth and differentiation in an 'in vivo' physiologically controlled situation. Various hepatotrophic factors exert their actions in regenerating liver by changing the intracellular concentrations of 'second messengers' such as Ca²⁺, cyclic AMP and cyclic GMP [1-3]. These second messengers, in turn, have effects on specific enzymes, receptors and other proteins, leading to the generation of physiological responses. On the other hand, PKC plays a crucial role in signal transduction for a variety of biologically active substances which trigger cellular functions and proliferation [4]. This enzyme is present in various tissues and cell types [5], and is usually activated by 1,2-diacylglycerol, which is released during the

Correspondence address: Y. Sasaki, First Department of Medicine, Osaka University Medical School, 1-1-50 Fukushima, Fukushima-ku, Osaka 553, Japan

Abbreviations: PKC, protein kinase C; CCl₄, carbon tetrachloride; BrdU, bromo-deoxyuridine; CLV, centrilobular vein; PV, portal vein.

process of phosphoinositide breakdown induced by receptor-mediated stimulation of many kinds of hormones, neurotransmitters and growth factors [6]. Accordingly, PKC may share the second messengers involved in liver regeneration and play an important role in mediating the biological actions of hepatotrophic factors. In this study, purification of PKC and immunohistochemical analysis were performed to determine whether, and if so how, PKC is activated in a hepatic lobule during liver regeneration induced by CC14 administration.

2. MATERIALS AND METHODS

2.1. Preparation of animals

Fifty-one male Sprague-Dawley rats, weighing 200-250 g, were used in this study. In order to induce liver regeneration, forty-five rats were given a single intragastric dose, 0.5 ml, of a 1:1 (v/v) mixture of CCl₄ in mineral oil per 100 g body weight, intragastrically. No treatment except mineral oil administration (1 ml per 100 g body weight) was given to the remaining six rats, which formed the normal group. At 24 h, 48 h and 7 days after the treatment, three rats were processed for the partial purification of PKC. On the other hand, at 6 h, 12 h, 24 h, 48 h, 72 h and 7 days after the administration, three fasted rats were subjected to immunohistochemical analysis of PKC. In order to

detect DNA replication after CCL administration, the other three rats were injected intravenously with BrdU [7] at the dose of 30 mg/kg body weight 1 h before being killed. The rats in the normal group were similarly prepared. The protocol for this study was approved by the Animal Studies Committee of Osaka University.

2.2. Enzyme purification and assays

Rat liver PKC was purified and resolved into two fractions, types II and III, by chromatography on a hydroxyapatite column, which was connected to a high-performance liquid chromatography (Pharmacia FPLC) system, under the conditions described previously [8]. The type II and III PKCs correspond to the β I- plus β II- and α subspecies, respectively [9]. PKC was assayed by measuring the incorporation of 32 P₁ into H₁ histone from [γ - 32 P]ATP in the presence of phosphatidylserine (8 μ g/ml), diolein (0.8 μ g/ml) and CaCl₂ (0.5 mM) under the conditions given previously [8]. Basal activity was measured in the presence of 0.5 mM EGTA instead of phosphatidylserine, diolein and Ca²⁺. Protein contents were determined by the method of Lowry et al. [10].

2.3. Immunohistochemical analysis

The procedures and conditions for immunohistochemical analysis in this study were described in detail elsewere [11,12]. Using synthetic oligopeptides specific for the predicted amino acid sequences of the C-terminal portions of the PKC α , β I-and β II-subspecies (α peptide residues 662-672; β I-peptide residues 661-671; β II-peptide residues 660-673), polyclonal antisera were raised in New Zealand White rabbits. Detailed procedures and properties of these antisera were described [13,14]. Sections from rats injected with BrdU were examined for DNA replication with a cell proliferation kit (Amersham, UK).

3. RESULTS

3.1. Partial purification of PKC

Fig.1 shows representative hydroxyapatite column chromatography of PKC from normal and treated rat livers. Two distinct types of PKC activity were obtained. The material of the first and second peaks from liver was eluted in fractions 30 through 38, and fractions 50 through 64, respectively, and this elution profile was highly reproducible. The activity of the material of the second peak increased to a peak at 24 h and then decreased, having returned to an almost basal level




Fig.1. Hydroxyapatite column chromatography of PKC from normal and treated rat livers. Rat liver PKC was purified by DE-52 and hydroxyapatite column chromatographies, and the fractions from the hydroxyapatite column were assayed as described in section 2. PKC from normal liver (A), liver 24 h after CCl₄ administration (B), liver 48 h after CCl₄ administration (C), and liver 7 days after CCl₄ administration (D).


(•—•) PKC activity in the presence of phosphatidylserine, diolein and CaCl₂; (C—O) PKC activity in the presence of EGTA instead of phosphatidylserine, diolein and CaCl₂; (C—) potassium phosphate.


7 days after treatment, while that of the first peak material remained almost unchanged. The kinase activity in these fractions was almost entirely Ca²⁺-and phospholipid-dependent.

3.2 Immunohistochemical detection of PKC and DNA replication

In normal liver, hepatocytes immunostained for the PKC α subspecies were diffusely distributed within a hepatic lobule (fig.2A). Immunoreactive structures were mainly localized in cell membranes of hepatocytes. The observation for the PKC β I-or PKC β II-subspecies was similar to that for the PKC α subspecies (data not shown). At 6 h after CCl₄ administration, heterogeneity of immuno-

Fig. 2. Immunohistochemical localization of the PKC α subspecies in normal rat liver and rat liver at 6 h after CCl₄ administration. In normal liver, hepatocytes immunostained for the PKC α subspecies are diffusely distributed within a hepatic lobule (A). Immunoreactive structures are mainly localized in the cell membranes of hepatocytes. Heterogeneity of immunostaining first becomes evident at 6 h after the treatment. The few hepatocytes stained for the PKC α subspecies are detected predominantly in the pericentral and mediolobular zones (B). Immunoreactive structures in these cells are localized not only in the cell membrane but also throughout the cytoplasm. Magnification: \times 90 in A; \times 45 in B.








Fig. 3. Immunohistochemical localization of the PKC α subspecies in rat liver at 24 h after CCl₄ administration. The number of hepatocytes immunostained for the PKC α subspecies has become maximal, with the development of clear zonal heterogeneity (A). Note that macrophages are also stained for the PKC α subspecies (B, arrows). Control reactions involving incubation with rabbit IgG instead of the first antiserum (C) and omission of the first antiserum (data not shown) are negative. Magnification: \times 25 in A; \times 50 in B, C.

staining first became evident. The few hepatocytes were intensely stained for the PKC α subspecies, predominantly in the pericentral and mediolobular zones (fig.2B). Immunoreactive structures in these cells were localized not only in the cell membrane

but also throughout the cytoplasm. At 24 h after treatment, the number of hepatocytes stained for the PKC α subspecies (fig.3A) became maximal, with the development of clear zonal heterogeneity. Immunostained hepatocytes were observed around




Fig. 4. Immunohistochemical localization of PKC and BrdU in rat liver at 48 h after CCL administration. Hepatocytes immunostained for the PKC α subspecies can be seen around areas showing a fatty change and/or ballooning in the pericentral and mediolobular zones (A). Heterogeneous staining is also evident for the PKC β I- (B) or β II- (C) subspecies, but the intensity of immunostaining is very weak compared with the case of the PKC α subspecies. The nuclei of some hepatocytes are immunostained for BrdU, which is indicative of ongoing DNA synthesis (D). The labeled nuclei are detected around areas showing pathological changes. Magnification: \times 32.5 in A, B, C; \times 16.3 in D.

areas where cell necrosis and/or a fatty change were observed. In addition, macrophages were also intensely stained for the PKC α subspecies (fig. 3B, arrows). Control reactions involving incubation with rabbit IgC instead of the first antiserum (fig.3C) and omission of the first antiserum (data not shown) were negative. At 48 h after administration, hepatocytes immunostained for the PKC α subspecies were detected around areas showing a fatty change and/or ballooning in the pericentral and mediolobular zones (fig.4A). The number of immunostained hepatocytes was descreased, as compared with that at 24 h after treatment, while the zonal heterogeneity of immunostaining remained. A heterogeneous immunostaining pattern was also recorded for the PKC β I- (fig. 4B) or β II- (fig.4C) subspecies, whereas the intensity of immunostaining was weak compared with the case of the PKC α subspecies. On the other hand, the nuclei of some hepatocytes were stained for BrdU, which was indicative of ongoing DNA synthesis (fig.4D). The labeled nuclei were detectable predominantly around areas showing pathological changes in the mediolobular and pericentral zones. Finally, at 72 h after treatment, immunoreactive structures were only detected in the cell membrane of hepatocytes, as observed in normal liver (data not shown).

4. DISCUSSION

The present study is the first demonstration that the activity of the PKC α subspecies increased prior to the initiation of DNA synthesis during liver regeneration induced by CCl₄ administration. This change in the activity of the PKC α subspecies supported the finding on immunohistochemical analysis that the number of immunostained hepatocytes increased, with a peak at 24 h after CCL administration, followed by DNA synthesis. Immunohistochemical analysis also showed that the PKC α subspecies was activated around areas showing pathological changes, and the distribution of hepatocytes expressing the PKC α subspecies was roughly coincident with that of those exhibiting DNA synthesis. Taking all the results together, it is suggested that the PKC α subspecies is the dominant PKC subspecies involved in crucial events regulating cell growth during liver regeneration. On the other hand, the present findings on

PKC enzyme assaying and immunohistochemical analysis indicate that the contribution of the PKC β I- and β II-subspecies to liver regeneration is negligible, compared with that of the PKC α subspecies. The precise mechanisms underlying activation of the PKC α subspecies and its functional roles in hepatocytes during liver regeneration remain unknown. Some of the hepatotrophic factors would cause the receptor-mediated hydrolysis of inositol phospholipids, resulting in activation of PKC. Vasopressin, angiotensin and epinephrine, defined as competence factors for cellular growth [15], may activate PKC, and then the activated PKC may mediate the sequence of early events in cellular proliferation of the liver, as speculated for various tissues and cell lines [6,16-21]. In addition, the activated PKC modulates binding and the phosphorvlation of receptors for EGF [22,23]. which is defined as a progression factor [15]. The modulation of the EGF receptor by PKC may provide a mechanism whereby competence factor(s) and progression factor(s) can act sequentially in stimulating cell growth. In this way, activation of PKC during liver regeneration may mediate and regulate the sequence of events concerning the competence and progression of cellular proliferation of the liver. Further investigations are required to clarify the functional role of the PKC α subspecies during liver regeneration.

Acknowledgments: We thank Dr Akira Kishimoto, Department of Biochemistry, Kobe University School of Medicine, for generous gifts of antisera and for his advice and technical assistance with partial purification of PKC. This study was supported by a Grant-in-Aid from the Ministry of Education, Science and Culture, Japan.

REFERENCES

- [1] Bucher, N.L.R., Ratel, U. and Cohen, S. (1978) in: Hepatotrophic factors. Ciba Foundation Symposium, pp. 95-110.
- [2] Leffert, H.L., Koch, K.S., Moran, T. and Rubalcava, B. (1979) Gastroenterology 76, 1470-1482.
- [3] Earp, H.S. and O'Keefe, E.J. (1981) J. Clin. Invest. 67, 1580-1583.
- [4] Nishizuka, Y. (1984) Nature 308, 692-697.
- [5] Nishizuka, Y. (1988) Nature 334, 661-665.
- [6] Rozengurt, E. (1986) Science 234, 161-166.
- [7] Garzner, H.G. (1982) Science 218, 474-475.
- [8] Kikkawa, U., Go, M., Koumoto, J. and Nishizuka, Y. (1986) Biochem. Biophys. Res. Commun. 135, 636-643.

- [9] Kikkawa, U., Ono, Y., Ogita, K., Fujii, T., Asaoka, Y., Sekiguchi, K., Kosaka, K., Igarashi, K. and Nishizuka, Y. (1987) FEBS Lett. 217, 227-231.
- [10] Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951) J. Biol. Chem. 193, 265-275.
- [11] Sasaki, Y., Hayashi, N., Morita, Y., Ito, T., Kasahara, A., Fusamoto, H., Sato, N., Tohyama, M. and Kamada, T. (1989) Hepatology, in press.
- [12] Sternberger, L.A., Hardy, P.H., jr and Cuculis, J.J. (1970) J. Histochem. Cytochem. 18, 315-333.
- [13] Kosaka, Y., Ogita, K., Ase, K., Nomura, H., Kikkawa, U. and Nishizuka, Y. (1988) Biochem. Biophys. Res. Commun. 151, 973-981.
- [14] Shearman, M.S., Naor, Z., Kikkawa, U. and Nishizuka, Y. (1987) Biochem. Biophys. Res. Commun. 147, 911-919.

- [15] Stiles, C.D., Capone, G.T., Scher, C.D., Antoniades, H.N., Van Wyk, J.J. and Pledger, W.J. (1979) Proc. Natl. Acad. Sci. USA 76, 1279-1283.
- [16] Bocckino, S.B., Blackmore, P.F. and Exton, J.H. (1985)J. Biol. Chem. 260, 14201-14207.
- [17] Vara, F. and Rozengurt, E. (1985) Biochem. Biophys. Res. Commun. 130, 646-653.
- [18] Trevillyan, J.M., Kulkarni, R.K. and Byus, C.V. (1984) J. Biol. Chem. 259, 897-902.
- [19] Kohno, M. (1985) J. Biol. Chem. 260, 1771-1779.
- [20] Greenberg, M.E. and Ziff, E.B. (1984) Nature 311, 433-438.
- [21] Kelley, K., Cochran, B.H., Stiles, C.D. and Leder, P. (1983) Cell 35, 603-610.
- [22] Cochet, C., Gill, G.M., Meisenhelder, J., Cooper, J.A. and Hunter, T. (1984) J. Biol. Chem. 259, 2553-2558.
- [23] McCaffrey, P.G., Friedman, B. and Rosner, M.R. (1984) Proc. Natl. Acad. Sci. USA 259, 12502-12507.